<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Nov. 15, 2018 (HealthDay News) — For patients with diabetes mellitus (DM) with multivessel coronary disease (MVD), coronary revascularization with coronary artery bypass grafting (CABG) is associated with lower all-cause mortality than percutaneous coronary intervention with drug-eluting stents (PCI-DES) in the long term, according to a study published online Nov. 11 in the Journal of the American College of Cardiology<\/i>. The research was published to coincide with the annual meeting of the American Heart Association, held from Nov. 10 to 12 in Chicago.<\/p>\n
Michael E. Farkouh, M.D., from the University of Toronto, and colleagues examined long-term survival of DM patients with MVD undergoing coronary revascularization. A total of 1,900 patients with DM and MVD were randomly assigned to undergo PCI-DES or CABG as part of the FREEDOM trial. The FREEDOM Follow-On study included 943 patients with a median follow-up of 7.5 years.<\/p>\n
The researchers identified 314 deaths during follow-up (204 deaths in the original trial; 110 in the FREEDOM Follow-On). All-cause mortality was significantly elevated in the PCI-DES group versus the CABG group (24.3 versus 18.3 percent; hazard ratio, 1.36; 95 percent confidence interval, 1.07 to 1.74; P = 0.01). All-cause mortality was 23.7 percent in the PCI-DES group and 18.7 percent in the CABG group among patients with extended follow-up (hazard ratio, 1.32; 95 percent confidence interval, 0.97 to 1.78; P = 0.076).<\/p>\n
“These findings provide clear evidence that CABG plus standard medical therapy is the optimal treatment path for patients with diabetes and extensive coronary disease,” Farkouh said in a statement.<\/p>\n
Several authors disclosed financial ties to the medical device industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n